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Summary
 
Signal transducer and activator of transcription (STAT)5 is constitutively activated in BCR/
ABL-expressing cells, but the mechanisms and functional consequences of such activation are
unknown. We show here that BCR/ABL induces phosphorylation and activation of STAT5
by a mechanism that requires the BCR/ABL Src homology (SH)2 domain and the proline-rich
binding site of the SH3 domain. Upon expression in 32Dcl3 growth factor–dependent myeloid
precursor cells, STAT5 activation–deficient BCR/ABL SH3
 
1
 
SH2 domain mutants func-
tioned as tyrosine kinase and activated Ras, but failed to protect from apoptosis induced by
withdrawal of interleukin 3 and/or serum and did not induce leukemia in severe combined im-
munodeficiency mice. In complementation assays, expression of a dominant-active STAT5B
mutant (STAT5B-DAM), but not wild-type STAT5B (STAT5B-WT), in 32Dcl3 cells trans-
fected with STAT5 activation–deficient BCR/ABL SH3
 
1
 
SH2 mutants restored protection
from apoptosis, stimulated growth factor–independent cell cycle progression, and rescued the
leukemogenic potential in mice. Moreover, expression of a dominant-negative STAT5B mu-
tant (STAT5B-DNM) in 32Dcl3 cells transfected with wild-type BCR/ABL inhibited apopto-
sis resistance, growth factor–independent proliferation, and the leukemogenic potential of these
cells. In retrovirally infected mouse bone marrow cells, expression of STAT5B-DNM inhib-
ited BCR/ABL-dependent transformation. Moreover, STAT5B-DAM, but not STAT5B-
WT, markedly enhanced the ability of STAT5 activation–defective BCR/ABL SH3
 
1
 
SH2
mutants to induce growth factor–independent colony formation of primary mouse bone marrow
progenitor cells. However, STAT5B-DAM did not rescue the growth factor–independent col-
ony formation of kinase-deficient K1172R BCR/ABL or the triple mutant Y177F
 
1
 
R522L
 
1
 
Y793F BCR/ABL, both of which also fail to activate STAT5. Together, these data demonstrate
that STAT5 activation by BCR/ABL is dependent on signaling from more than one domain and
document the important role of STAT5-regulated pathways in BCR/ABL leukemogenesis.
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T
 
he
 
 bcr/abl
 
 chimeric oncogenes are generated by a recip-
rocal translocation between chromosomes 9 and 22
(Philadelphia chromosome) that fuses a truncated 
 
bcr
 
 gene to
sequences upstream of the second exon of c-
 
abl
 
 (1). The 
 
bcr/
abl
 
 genes encode the constitutively active p210 and p185
BCR/ABL tyrosine kinases (2, 3), which play essential roles in
 
the pathogenesis of chronic myelogenous leukemia (CML)
 
1
 
and Philadelphia
 
1
 
 (Ph
 
1
 
) acute lymphoblastic leukemia (4).
Expression of BCR/ABL oncoproteins in hematopoietic
cells induces resistance to apoptosis (5, 6), growth factor in-
dependence (7), alterations in cell–cell and cell–matrix in-
teractions (8, 9), and leukemogenesis (10–12). This pheno-
type is associated with enhanced expression/activation of
several effectors (13, 14), such as Ras (15, 16), Rac (17),
Raf-1 (18), phosphatidylinositol-3 kinase (PI-3k; 19–21),
 
tem; DAM, dominant-active mutant; DNM, dominant-negative mutant;
EMSA, electrophoretic mobility shift assay; PI-3k, phosphatidylinositol-3
kinase; P.Tyr, phosphotyrosine; RT, reverse transcription; SH, src homol-
ogy; STAT, signal transducer and activator of transcription; WT, wild-type.
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); BrdU, 5-bromo-2
 
9
 
-deox-
yuridine; CML, chronic myelogenous leukemia; CNS, central nervous sys- 
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Akt (21), Bcl-2 (22), nuclear factor (NF)-
 
k
 
B (23), and signal
transducers and activators of transcription (STATs; 24–27).
Although the activity of most of these effectors is required
for the BCR/ABL-mediated leukemogenesis, the role of
STATs is unknown. Thus far, seven mammalian STATs (1,
2, 3, 4, 5A, 5B, and 6) have been identified. These seven
STATs constitute a family of signal transduction proteins that,
upon tyrosine phosphorylation, dimerize, translocate to the
nucleus, and bind to specific response elements in the promot-
ers of target genes to induce their transcription (28, 29).
Among the STAT proteins, STAT5A and STAT5B are
 
z
 
95% identical in amino acid (aa) sequence and have both
distinct and redundant roles in cytokine responses (30–32).
STATs are activated in cells stimulated with growth factors
such as IL-2 (33, 34), IL-3 (35, 36), IL-5 (36), GM-CSF (36),
erythropoietin (37), insulin (38), epidermal growth factor (38),
growth hormone (40), and hepatocyte growth factor (41), and
in cells expressing activated nonreceptor tyrosine kinases such
as v-ABL (42), v-SRC (43), LCK (44), and BMX (45). STAT
activity is regulated by tyrosine and also by serine phosphory-
lation (46, 47). In addition, COOH-terminal truncated forms
of STAT described in different cell types (48–50) may act in a
dominant-negative manner to regulate STAT activity.
The biological consequences of STAT activation in hema-
topoietic cells are largely unknown; however, a role for
STATs in regulation of proliferation (48, 51, 52) and resistance
to apoptosis (34) has been suggested. Constitutive activation of
STATs has been found in malignant lymphoma and leukemia
cells (53, 54), implicating these proteins in leukemogenesis.
STATs (mainly STAT5A and STAT5B, but also STAT1
and STAT3) are also activated in hematopoietic cell lines
expressing BCR/ABL (24–27) and in CML cells (55).
However, thus far no direct evidence of a role for STATs
in BCR/ABL-dependent leukemogenesis has been ob-
tained. We show here that most of the BCR/ABL-induced
STAT activity is due to STAT5. Activation of STAT5 by
BCR/ABL involves the SH3 and SH2 domains of BCR/
ABL, and is distinct from mechanism(s) responsible for Ras
stimulation. Moreover, STAT5 activation is involved in
antiapoptotic activity and cell cycle progression induced by
BCR/ABL, and is important for BCR/ABL-mediated leu-
kemogenesis in vitro and in vivo.
 
Materials and Methods
 
Retroviral Constructs.
 
The pSR
 
a
 
p210BCR/ABL wild-type
(WT) and the kinase-deficient K1172R, 
 
D
 
SH3, 
 
D
 
SH2, P1013L,
and R1053L BCR/ABL mutants have been described previously
(9, 21). The 
 
D
 
SH3
 
1
 
D
 
SH2 (deletion of both the SH3 and the
SH2 domains), P1013L
 
1
 
D
 
SH2 (single aa substitution in the SH3
domain and deletion of the SH2 domain), 
 
D
 
SH3
 
1
 
R1053L (dele-
tion of the SH3 domain and single aa substitution in the SH2 do-
main), P1013L
 
1
 
R1053L (single aa substitutions in the SH3 and
SH2 domains, respectively), p210BCR/ABL mutants were gen-
erated by replacing the EcoRI-KpnI (containing the SH3 do-
main) and the KpnI-BsrGI (containing the SH2 domain) frag-
ments of BCR/ABL with the corresponding fragments containing
the indicated mutation or lacking the region corresponding to
the SH3 or the SH2 domain. All constructs were sequenced to
 
confirm the presence of specific mutations. The pSR
 
a
 
p185
BCR/ABL triple mutant (TM) (Y177F
 
1
 
R522L
 
1
 
Y793F) and
 
D
 
176–426 mutant (56, 57) were obtained from Dr. A.M. Pen-
dergast (Duke University Medical Center, Durham, NC). WT
STAT5B and STAT5B dominant-active mutant (DAM)
(H295R
 
1
 
S715F) were cloned into the pMX-puro retroviral vec-
tor carrying the puromycin-resistance gene (58). COOH-terminal
truncated STAT5B (
 
D
 
STAT5) dominant-negative mutant (DNM)
was a gift from Dr. A. Mui (DNAX, Palo Alto, CA) (48). The mu-
tant was cloned into the pMX-puro vector.
 
Electroporation of 32Dcl3 Cells.
 
Constructs were electroporated
into 32Dcl3 growth factor–dependent murine myeloid precursor
cells (59) growing in IMDM-CM (IMDM supplemented with
10% FBS, 2 mM 
 
l
 
-glutamine, penicillin/streptomycin [100 
 
m
 
g/ml
each], and 15% WEHI-conditioned medium [WEHI-CM] as a
source of IL-3). BCR/ABL and/or STAT5B-expressing clones
were obtained after selection in G418 (1 mg/ml)- or puromycin
(2 
 
m
 
g/ml)-containing medium, respectively, and were maintained in
IMDM-CM. Expression of BCR/ABL in G418-resistant mixed cell
transfectants and in individual clones was confirmed by Western blot
analysis with an anti-ABL antibody (see below). Ectopic expression
of STAT5B-WT and STAT5B-DAM in the clones was confirmed
by reverse transcription (RT)-PCR using primers spanning the
EcoRI cloning site in the construct, since STAT5 expression was
similar in the clones and in the nontransfected cells. In addition,
STAT5B-DAM expression in transfected cells was confirmed by
electrophoretic mobility shift assay (EMSA) detecting STAT DNA
binding activity in growth factor– and serum-starved cells.
 
Retroviral Infections of 32Dcl3 Cells and Bone Marrow Cells.
 
In-
fections were performed as previously described (21, 60) with
some modifications. In brief, helper-free retroviruses were gener-
ated by transiently transfecting retroviral vectors into BOSC23
cells as described (61). 24 h after transfection, 5 
 
3
 
 10
 
6
 
 bone mar-
row cells from C57BL/6TacfBR mice (The Jackson Laboratory)
treated 6 d before cell harvest with 5-fluorouracil (150 mg/kg
body wt) were added to the monolayer of BOSC23 cells trans-
fected with BCR/ABL- and/or STAT5B-containing vectors or
with the insert-less vector and cocultivated for 72 h in 4 ml of
IMDM supplemented with 10% FBS, 
 
l
 
-glutamine, penicillin/
streptomycin in the presence of recombinant IL-3, Kit ligand, and
IL-6 (Genetics Institute), and polybrene (2 
 
m
 
g/ml) as previously
described (21, 60). Freshly established BCR/ABL-positive 32Dcl3
clones were infected in the presence of IL-3 by cocultivation with
BOSC23 cells transfected with STAT5B-DNM containing vector
or with insert-less vector. Bulk cultures of hematopoietic cells ob-
tained 72 h after infection were used for the experiments. Expres-
sion of BCR/ABL was confirmed by Western blot analysis with
anti-ABL antibody. STAT5B-WT expression was documented by
RT-PCR using primers spanning the EcoRI cloning site. Expres-
sion of STAT5B-DAM was monitored by EMSA assay and by
RT-PCR using primers spanning the EcoRI cloning site. Expres-
sion of STAT5B-DNM (
 
D
 
STAT) was detected by RT-PCR us-
ing primers spanning the NotI cloning site in the construct thus al-
lowing amplification of a fragment corresponding to the ectopically
expressed C-terminal truncated STAT5B, and by Western blot
analysis with anti-STAT5 antibody raised against aa 451–649
(CAT. No. S21520; Transduction Labs.). Moreover, STAT5B-
DNM was shown to inhibit BCR/ABL-induced STAT5 DNA
binding activity in the transfected cells, and the samples in which
the inhibition was 
 
.
 
75% were used in the studies.
 
Western Blot Analysis.
 
Expression of BCR/ABL and STAT5
was detected in total cell lysates by Western blot analysis with
anti-ABL (Oncogene Science) and anti-STAT5 (Oncogene Sci- 
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ence; Santa Cruz Biotechnology, Inc.; and Transduction Labs.)
antibodies, respectively. Tyrosine phosphorylated proteins and
actin were detected using anti-phosphotyrosine (P.Tyr) antibod-
ies (Upstate Biotechnology, Inc.; and Oncogene Science) and
anti-actin (Santa Cruz Biotechnology, Inc.), respectively.
 
BCR/ABL Kinase Assay.
 
Cells were starved of growth fac-
tors and serum for 3 h. BCR/ABL kinase activity was deter-
mined in anti-ABL immunoprecipitates from parental 32Dcl3
cells and wild-type or mutant BCR/ABL-expressing cells, using
5 
 
m
 
g enolase as substrate (62).
 
Ras Assay.
 
Ras activation was determined by measuring GTP-
bound Ras as previously described (15).
 
STAT Functional Assays.
 
The DNA binding activity of STAT
was examined by EMSA as previously described (9) using the
Fc
 
g
 
RI GAS motif as a probe. The sequence of the probe and the
nonspecific competitor were as described (9). Supershift assays
were performed using anti-STAT1, -STAT3, and -STAT5 mAbs
(Santa Cruz Biotechnology, Inc.). STAT5-dependent transacti-
vation was examined by luciferase assay (36, 48). In brief,
Tk
 
2
 
ts13 hamster fibroblasts were cotransfected with the expres-
sion vector (wild-type or mutant) BCR/ABL or with the insert-
less vector along with the STAT5-responsive luciferase reporter
construct (
 
b
 
-casein-Luc) and the expression plasmids for
STAT5B and 
 
b
 
-galactosidase (
 
b
 
-Gal). 36 h after transfection,
cells were starved from serum (0.1% BSA) for 48 h and harvested
for the luciferase assay using Dual-Luciferase Reporter Assay Sys-
tem (Promega) according to the manufacturer’s protocol. For
each transfection, luciferase activity was normalized using 
 
b
 
-Gal
activity as an internal control.
 
Apoptosis Assay.
 
Susceptibility to apoptosis induced by growth
factor and/or serum withdrawal was measured as described (17)
with some modifications. In brief, cells (2 
 
3
 
 10
 
5
 
/ml) were incu-
bated in IMDM supplemented with 2 mM 
 
l
 
-glutamine, penicil-
lin/streptomycin (100 
 
m
 
g/ml each), and 0.1% BSA or 10% FBS
for 24 and 48 h. The percentage of apoptotic cells was deter-
mined by using the TACS1 Klenow in situ apoptosis detection
kit (Trevigen) according to the manufacturer’s protocol.
 
Cell Cycle Analysis.
 
Cells (10
 
6
 
) were starved of IL-3 (10%
FBS) or IL-3 and serum (0.1% BSA) for 12 h and cell cycle anal-
ysis was performed as previously described (63) using propidium
iodide to stain DNA.
 
DNA Synthesis.
 
This parameter was determined using a
5-bromo-2
 
9
 
-deoxyuridine (BrdU) detection and labeling kit
(Boehringer Mannheim). In brief, cells were starved of IL-3 (10%
FBS) or IL-3 and serum (0.1% BSA) for 8 h and then incubated
with 10 
 
m
 
M BrdU for the next 4 h. Cytospin slides were pre-
pared and fixed in 94.5% ethanol containing 5% acetic acid and
0.5% Triton X-100. BrdU was detected by staining with mouse
anti-BrdU mAb followed by sheep anti–mouse IgG-FITC. Nu-
clei were counterstained with 500 
 
m
 
g/ml bisbenzimide H33258
(Sigma Chemical Co.). Slides were mounted in Vectashield
mounting medium (Vector Labs.) and the percentage of BrdU-
positive cells was determined using a Zeiss microscope equipped
for epifluorescence mode. 500 cells per cytospin were counted
from randomly selected fields.
 
Leukemogenesis in SCID Mice.
 
ICR SCID male mice (Taconic
Farms, Inc.) were injected intravenously with 5 
 
3
 
 10
 
6
 
 32Dcl3 cells
expressing the indicated BCR/ABL and/or STAT proteins. 4 wk
later, four to six mice per group were killed and organs were ana-
lyzed macroscopically and microscopically for the presence of leu-
kemia (21). Terminally ill mice were also killed and examined for
the development of leukemia. Tissue sections from bone marrow,
spleen, liver, lungs, kidneys, and brain were fixed in phosphate-
buffered formalin and embedded in paraffin blocks. Two levels
from each block were cut and stained with hematoxylin and eosin.
In addition, selected slides were stained for chloroacetate esterase
(Leder stain) to assess myeloid differentiation of blast cells.
 
Results
 
STAT5 Activation Requires Functional SH3 and SH2 Domains
of BCR/ABL.
 
To investigate mechanisms and functional
consequences of STAT activation by BCR/ABL, we first
identified BCR/ABL mutants defective in STAT activa-
tion. Based on the findings that v-Src requires an intact ki-
nase domain and both SH3 and SH2 domains to stimulate
STATs (43), the following BCR/ABL mutants were used:
the kinase-deficient K1172R mutant; the 
 
D
 
SH2 mutant
lacking the entire SH2 domain (aa 1030–1120); the SH2
FLVRES motif mutant R1053L; the 
 
D
 
SH3 mutant lacking
the entire SH3 domain (aa 959–1020); the SH3 domain
mutant P1013L; the 
 
D
 
SH3
 
1D
 
SH2 mutant lacking both
the SH3 and SH2 domains (aa 959–1020 and aa 1030–1120);
the P1013L
 
1
 
R1053L mutant carrying single aa substitu-
tions in both the SH3 and the SH2 domains; and the
 
D
 
SH3
 
1
 
R1053L and P1013L
 
1
 
D
 
SH2 mutants lacking ei-
ther the SH3 or the SH2 domain and containing a single aa
substitution in the other domain.
After transfection of growth factor–dependent 32Dcl3
murine myeloid precursor cells, G418-resistant clones were
selected and examined for the expression of BCR/ABL
proteins (Fig. 1). G418-resistant BCR/ABL-expressing cell
clones (three to six different clones for each BCR/ABL
mutant) were then starved of growth factors and serum and
nuclear extracts were examined for activation of STAT
DNA binding activity using the STAT binding site from
the Fc
 
g
 
RI promoter as a probe. Cells expressing full-length
BCR/ABL (WT) but not the control parental 32Dcl3 cells,
or cells expressing the K1172R kinase-deficient BCR/
ABL mutant showed STAT DNA binding activity (Fig. 2,
top). The specificity of the DNA-protein complex was in-
vestigated by EMSA in which an excess of unlabeled spe-
cific or nonspecific oligonucleotide was used as competitor.
The DNA–protein complex was not detectable, or was
markedly inhibited in the presence of 100- or 10-fold ex-
cess of specific competitor, respectively (data not shown).
STAT1, STAT3, STAT4, STAT5, and STAT6 have previ-
ously been shown to bind efficiently to the probe, and
STAT1, STAT3, and STAT5 have been reported to be acti-
vated by p210 BCR/ABL (24–27, 55). In supershift assays
performed to determine which STATs were involved in
DNA-protein interaction, most of the complex was super-
shifted by the anti-STAT5 antibody, whereas no supershift
was detected in the presence of the anti-STAT3 or the anti-
STAT1 antibody (data not shown). In addition, when anti-
STAT immunoprecipitates were blotted with the anti-P.Tyr
antibody, STAT5 phosphorylation was prominent, STAT1
was weakly phosphorylated, and STAT3 was not detected in
its phosphorylated form (data not shown). Thus, STAT5
represents the majority of the STAT activity induced by
BCR/ABL, in accordance with other reports (24–27). 
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BCR/ABL mutants deleted in either the SH3 (
 
D
 
SH3) or
the SH2 (
 
D
 
SH2) domain, or those carrying a single aa substi-
tution in the SH3 or the SH2 domain (P1013L or R1053L,
respectively), were able to activate STAT5 DNA binding
activity (Fig. 2, top, and data not shown). However,
deletion of both the SH3 and the SH2 domains (
 
D
 
SH3
 
1
D
 
SH2 BCR/ABL mutant) completely abolished the ability
to activate STAT5 (Fig. 2, top). Lack of STAT5 activation
was also observed in cells expressing the P1013L
 
1
 
D
 
SH2
BCR/ABL mutant, whereas 
 
D
 
SH3
 
1
 
R1053L and P1013L
 
1
 
R1053L BCR/ABL mutants activated STAT5 (Fig. 2, top).
Phosphorylation of STAT5 in IL-3 and serum-starved
32Dcl3 cells expressing wild-type and mutant BCR/ABL
proteins was monitored by Western blot analysis of anti-
STAT5 immunoprecipitates with anti-P.Tyr antibody and
correlated with STAT5 DNA binding activity (Fig. 2, mid-
dle). Lack of STAT5 activation in clones expressing 
 
D
 
SH3
 
1
 
D
 
SH2 or P1013L
 
1
 
D
 
SH2 BCR/ABL mutants was not due
to a general metabolic defect of the transfected cells, because
it was fully restored by addition of IL-3 (data not shown).
Parental 32Dcl3 cells and cells transfected with kinase-
deficient K1172R BCR/ABL mutant expressed full-length
and COOH-terminal truncated STAT5 proteins, as indi-
cated by detecting two distinct bands in Western blotting
(using the anti-STAT5 antibody raised against aa 451–649)
of anti-STAT5 immunoprecipitates obtained with an anti-
body raised against the NH
 
2
 
 terminus (aa 5–24) of STAT5
(Fig. 2, middle). The upper band was also detected by an
antibody raised against the COOH terminus (aa 763–779)
of STAT5B (data not shown). Interestingly, the COOH-
terminal truncated STAT5 was usually detected in parental
32Dcl3 cells and in cells expressing the kinase-deficient
BCR/ABL mutant but not in cells expressing wild-type
BCR/ABL or the various SH3
 
1
 
SH2 BCR/ABL mutants
retaining kinase activity (Fig. 2, middle).
To examine the ability of BCR/ABL mutants to modu-
late the transactivation activity of STAT5, a reporter plas-
mid carrying the luciferase gene under the control of the
STAT5-regulated 
 
b
 
-casein promoter (36, 48) was coex-
pressed in Tk
 
2
 
ts13 cells with wild-type STAT5 and the
various BCR/ABL plasmids, and the transactivation ability
of STAT5 was measured by luciferase assay. Stimulation of
STAT5 transactivation activity by BCR/ABL (wild-type
and mutants) correlated with their ability to induce STAT5
phosphorylation and DNA binding (Fig. 2, bottom).
Lack of STAT5 activation in cells expressing 
 
D
 
SH3
 
1
D
 
SH2 or P1013L1DSH2 BCR/ABL mutants was not due
to the inability of these mutants to function as tyrosine ki-
nase, since similar (albeit not identical) patterns of tyrosine
phosphorylated proteins were detected in lysates of cells
expressing wild-type BCR/ABL or SH31SH2 BCR/ABL
mutants unable to activate STAT5 (Fig. 3, top), and immu-
noprecipitated BCR/ABL mutants were able to phosphor-
ylate enolase in in vitro kinase assays (Fig. 3, middle). Like-
wise, lack of STAT5 activation was not the consequence
of detectable defects in Ras activation since the SH31SH2
BCR/ABL mutants, like WT BCR/ABL, were all able to
activate Ras (Fig. 3, bottom).
Abrogation of STAT5 Activity Impairs BCR/ABL-depen-
dent Protection from Apoptosis, Cell Cycle Progression, and Leu-
kemogenesis. STAT5 activation–deficient BCR/ABL mu-
tants (DSH31DSH2 and P1013L1DSH2) failed to protect
32Dcl3 cells from apoptosis induced by withdrawal of IL-3
(10% FBS) or of IL-3 and serum (0.1% BSA) (Fig. 4, top).
The BCR/ABL SH31SH2 mutants (DSH31R1053L and
P1013L1R1053L), which retain the ability to activate
STAT5, did not protect from apoptosis in IL-3– and serum-
deprived medium (0.1% BSA), as only a minority of cells
(15–25%) were alive after 48 h of culture (Fig. 4, top left).
However, these mutants provided significant protection
from apoptosis (50–60% of viable cells) in the presence of
serum (10% FBS; Fig. 4, top right) and the surviving cells
readily adapted to growth factor–free culture conditions
and proliferated without IL-3 (data not shown).
To determine if inhibition of STAT5 activity interferes
with the antiapoptotic effects of BCR/ABL, freshly estab-
lished 32Dcl3 clones expressing BCR/ABL were infected
with a retrovirus carrying STAT5B-DNM and were assessed
Figure 1. BCR/ABL expression in representative 32Dcl3 clones ex-
pressing WT or mutant BCR/ABL. BCR/ABL and c-Abl proteins were
detected by Western blotting with anti-ABL mAb. Parental 32Dcl3 cells
served as control.
Figure 2. Activation of STAT5
by BCR/ABL mutants. Parental
32Dcl3 cells (Control) and cells
expressing full-length (WT) or
mutant (D3  5 DSH3, D2  5
DSH2) BCR/ABL were starved
of IL-3 and serum for 5 h before
assaying STAT DNA binding ac-
tivity by EMSA using the GAS se-
quence as a probe (top). Results
are representative of five experi-
ments using individual clones and
mixed cell transfectants before
clonal selection. Tyrosine phos-
phorylation of STAT5 was de-
tected by Western blot analysis
with an anti-P.Tyr antibody of
anti-STAT5 immunoprecipitates
obtained using an antibody raised
against the STAT5 NH2 terminus
(middle, P.Tyr–STAT5). The presence of STAT5 in immunoprecipitates
was confirmed by Western blotting with an anti-STAT5 antibody raised
against aa 451–649 (middle, STAT5). (Bottom) STAT5 transactivation ac-
tivity was measured by luciferase assay in Tk2ts13 cells transiently transfected
with the indicated BCR/ABL expression plasmids along with the plasmids
carrying STAT5 and the luciferase reporter gene driven by the STAT5-reg-
ulated b-casein promoter. Luciferase activity is expressed in arbitrary units.
Results represent three independent experiments.1233 Nieborowska-Skorska et al.
72 h later for apoptosis in cultures deprived of IL-3 (10%
FBS) or IL-3 and serum (0.1% BSA). Approximately 60%
of the cells infected with the STAT5B-DNM retrovirus
underwent apoptosis 48 h after growth factor and/or serum
withdrawal (Fig. 4, middle).
Cell cycle analysis after 12 h of starvation from IL-3
(10% FBS) or IL-3 and serum (0.1% BSA) revealed a re-
duced proportion of cells in S phase and an increase in the
fraction of G0/G1 phase cells in STAT5 activation–defi-
cient BCR/ABL mutant (DSH31DSH2 and P1013L1
DSH2) expressing cells (Fig. 5, f and h) compared with
those expressing BCR/ABL WT (Fig. 5 b) or BCR/ABL
SH31SH2 mutants capable of activating STAT5 (Fig. 5,
d and e). Moreover, BrdU incorporation assay showed a
reduced rate of DNA synthesis in cells expressing STAT5
activation–deficient BCR/ABL SH31SH2 mutants (Fig. 5,
f and h), as compared with those expressing BCR/ABL
WT (Fig. 5 b) or BCR/ABL SH31SH2 mutants activating
STAT5 (Fig. 5, d and e). The changes in cell cycle distribu-
tion and DNA synthesis were dependent on the expression
of mutant BCR/ABL and not on differences in growth
Figure 3. Tyrosine kinase activity and Ras activation by BCR/ABL
proteins. Cells were treated as in Fig. 1 and the pattern of tyrosine phos-
phorylated proteins was analyzed in total cell lysates by Western blot anal-
ysis with anti-P.Tyr antibodies (top). In vitro kinase activity was assayed
in anti-ABL immunoprecipitates using g-[32P]ATP and enolase as sub-
strate (middle). Ras activation was measured in a standard GTP-loading
assay (bottom).
Figure 4. Antiapoptotic activ-
ity of BCR/ABL and/or STAT5B
proteins. 32Dcl3 cells (Control)
or cells expressing the indicated
BCR/ABL and STAT5 proteins
were starved of IL-3 (10% FBS)
or IL-3 and serum (0.1% BSA),
and assayed for apoptosis using in
situ apoptosis detection kit. Re-
sults represent mean 6 SD from
four different clones per group.
WT, full-length BCR/ABL.1234 Role of STAT5 in BCR/ABL Leukemogenesis
abilities of the clones, because all clones showed similar
proliferation rate in the presence of IL-3 (data not shown).
Inhibition of STAT5 function in BCR/ABL-positive
32Dcl3 cells by transient expression of STAT5B-DNM
caused a reduction of the percentage of cells in S and G2/M
phase and an increase of the percentage of cells in G0/G1
phase (Fig. 5 c) in comparison to cells expressing BCR/ABL
(Fig. 5 b) or BCR/ABL and WT STAT5B (data not shown).
Lack of STAT5 activation by BCR/ABL mutants corre-
lated with their reduced leukemogenic potential. SCID
mice injected with 32Dcl3 cells expressing WT BCR/ABL
died after 4–7 wk (Fig. 6, top) due to leukemia as con-
firmed at necropsy. Mice inoculated with cells expressing
BCR/ABL SH3 and/or SH2 mutants activating STATs
(DSH3, DSH2, DSH31R1053L, or P1013L1R1053L) suc-
cumbed to leukemia after 10–20 wk (Fig. 6, top). By con-
trast, mice injected with cells expressing STAT5 activation–
deficient BCR/ABL mutants (DSH31DSH2 and P1013L1
DSH2) did not develop leukemia after 20 wk, as confirmed
by histopathological examination of four mice per group, and
remained leukemia-free during a 6-mo observation period.
Inhibition of STAT5 activity by transient transfection of
the dominant-negative mutant impaired the leukemogenic
potential of BCR/ABL-expressing 32Dcl3 cells (Fig. 6,
middle). SCID mice injected with BCR/ABL-positive
STAT5B-DNM transient transfectants survived longer
(10–17 wk) than those inoculated with cells coexpressing
BCR/ABL and WT STAT5B (5–7 wk).
Constitutively Active STAT5B Mutant Rescues the Antiap-
optotic, Proliferative, and Leukemogenic Properties of STAT5 Ac-
tivation–deficient BCR/ABL SH31SH2 Mutants. To deter-
mine whether STAT5 is essential for the antiapoptotic
Figure 5. Effect of BCR/ABL
and/or STAT5B proteins on cell
cycle and DNA synthesis of
32Dcl3 cells. Cells were starved
of IL-3 (10% FBS) or IL-3 and
serum (0.1% BSA), and DNA
content and DNA synthesis were
determined by flow cytometry
after staining with propidium io-
dide, and by immunocytochemis-
try to detect incorporated BrdU,
respectively. 32Dcl3 parental cells
(a) and clones expressing WT
BCR/ABL (b), WT BCR/ABL
and STAT5B-DNM (c), DSH31
R1053L BCR/ABL (d), P1013L1
R1053L (e) DSH31DSH2 BCR/
ABL (f), DSH31DSH2 BCR/
ABL and STAT5B-DAM (g),
P1013L1DSH2 BCR/ABL (h),
P1013L1DSH2 and STAT5B-
DAM (i), and STAT5B-DAM
(j) were examined. Results rep-
resent three experiments using
different clones. Percentage of
cells in G0/G1, S, and G2/M
phase, and of cells incorporating
BrdU, are shown in upper right
corners.1235 Nieborowska-Skorska et al.
activity of BCR/ABL, STAT5B-DAM or STAT5B-WT
was introduced into 32Dcl3 parental cells or cells express-
ing BCR/ABL SH31SH2 mutants defective in STAT5
activation. 32Dcl3 cells expressing STAT5B-DAM, but not
cells expressing STAT5B-WT, were transiently resistant to
apoptosis induced by IL-3 and/or serum withdrawal (Fig.
4, bottom), but all died after 72–96 h. Cell cycle analysis af-
ter 12 h of starvation revealed that 32Dcl3 cells expressing
STAT5B-DAM did not proliferate in the absence of IL-3
and/or serum (Fig. 5 j). In contrast, STAT5B-DAM per-
manently rescued the apoptotic phenotype of IL-3 and/or
serum-starved 32Dcl3 cells expressing STAT5 activation–
deficient BCR/ABL SH31SH2 mutants (Fig. 4, bottom),
stimulated DNA synthesis and cell cycle progression in
serum- and/or IL-3–free medium (Fig. 5, g and i), and al-
lowed IL-3–independent proliferation (data not shown).
To determine whether restoration of growth factor inde-
pendence by STAT5B-DAM in 32Dcl3 cells expressing
the DSH31DSH2 or P1013L1DSH2 BCR/ABL mutant
would also rescue their leukemogenic potential, SCID
mice were injected intravenously with double-transfected
cells and monitored for the development of leukemia. 4 wk
after injection, organs taken from the mice were evaluated
by visual inspection and light microscopy for the presence
of leukemia. Consistent with previous studies (9), injection
with WT BCR/ABL-expressing cells resulted in extensive
leukemia involving both hematopoietic and nonhemato-
poietic organs in all four mice examined. Mice injected
with 32Dcl3 cells expressing the DSH31DSH2 or the
P1013L1DSH2 BCR/ABL mutant showed no evidence
of leukemia at 4 wk after cell inoculation (six and four mice
per group examined, respectively) and remained alive after
a 6-mo observation period. Similarly, mice injected with
cells expressing STAT5B-DAM also showed no signs of
leukemia at 4 wk after inoculation (five mice tested) and
remained alive after 6 mo of observation. In contrast, all nine
mice injected with 32Dcl3 cells coexpressing STAT5B-
DAM and the DSH31DSH2 or P10131DSH2 BCR/ABL
mutant developed leukemia within 4 wk. In bone marrow,
spleen, liver, lungs, and kidneys, the leukemia resembled
that caused by WT BCR/ABL, but was less extensive, e.g.,
liver typically showed scant periportal and sinusoidal in-
filtrates, and lungs showed patchy interstitial infiltrates
without formation of frank, large tumors. DSH31DSH2
or P1013L1DSH2 BCR/ABL- and STAT5B-DAM coex-
pressing cells more frequently involved meninges (six out
of nine) and even brain parenchyma (two out of nine), as
compared with BCR/ABL WT-expressing cells, which
only occasionally and focally involved meninges (one out
of four mice) at 4 wk after leukemia cell injection. Leuke-
mic cells in the terminally ill mice injected with cells coex-
pressing BCR/ABL mutant and STAT5B-DAM formed
invasive parenchymal foci within the central nervous sys-
tem (CNS) of 13 out of 15 animals analyzed, whereas only
small meningeal foci were observed in 12 out of 20 termi-
nally ill mice injected with BCR/ABL WT-expressing
cells. Mice inoculated with cells expressing DSH31DSH2
or P1013L1DSH2 BCR/ABL mutants and STAT5B-
DAM died of leukemia after 7–11 wk, whereas cells trans-
formed with BCR/ABL WT killed the mice in 4–7 wk
(Fig. 6, bottom).
STAT5 Activity Is Required for Growth Factor–independent
Colony Formation of BCR/ABL-expressing Bone Marrow
Cells. To determine whether STAT5 plays an essential
role in BCR/ABL-mediated transformation of bone marrow
cells, we tested whether STAT5B-DNM inhibits transfor-
mation of hematopoietic progenitor cells by WT BCR/
ABL, and whether STAT5B-DAM rescues the impaired
transformation potential of DSH31DSH2 and P1013L1
DSH2 BCR/ABL mutants. Bone marrow cells from 5-fluo-
rouracil–treated mice were infected with retroviral vectors
carrying the various BCR/ABL and/or STAT5B cDNAs,
and transformation was assessed by growth factor–indepen-
dent colony formation (21, 60). In the presence of thresh-
old concentrations of recombinant murine IL-3 (0.1 U/ml),
Figure 6. Survival of SCID mice injected with 32Dcl3 cells expressing
various BCR/ABL and/or STAT5B proteins. Mice were injected intra-
venously with 5 3 106 cells expressing the indicated BCR/ABL and/or
STAT5B proteins (3–5 clones, 5 mice/clone). Terminally ill mice were
killed and analyzed for the presence of leukemia.1236 Role of STAT5 in BCR/ABL Leukemogenesis
a high number of colonies formed from marrow cells in-
fected with a retrovirus encoding WT BCR/ABL; fewer
colonies formed in the absence of IL-3 (Fig. 7, bottom). Co-
infection of marrow cells with a STAT5B-WT or STAT5B-
DAM induced a moderate increase in BCR/ABL-depen-
dent colony formation (Fig. 7, bottom), whereas coinfection
with STAT5B-DNM inhibited colony formation induced
by WT BCR/ABL by z60% and z75% in the presence or
absence of IL-3, respectively. Upon infection of mouse
bone marrow cells with retroviruses carrying STAT5 acti-
vation–deficient BCR/ABL mutants (DSH31DSH2 and
P1013L1DSH2), no hematopoietic colonies formed in
methylcellulose in the absence of IL-3 and only few (as in
control groups) developed in cultures supplemented with
IL-3 (Fig. 7, bottom). However, coinfection of marrow
cells with the retroviruses carrying the DSH31DSH2 or
P1013L1DSH2 BCR/ABL mutant and STAT5B-DAM,
but not STAT5B-WT, induced large (data not shown),
and numerous (Fig. 7, bottom) colonies. Infection of mar-
row cells with the retrovirus carrying the STAT5B-DAM
alone did not stimulate the formation of growth factor–
independent colonies (Fig. 7, bottom). In addition, expres-
sion of STAT5B-DAM did not rescue the transformation-
deficient phenotype of the K1172R kinase-deficient
BCR/ABL mutant or of the BCR/ABL TM Y177F1
R522L1Y793F (Fig. 7, bottom), both of which failed to
activate STAT5 in 32Dcl3 cells (Fig. 2 and data not shown)
and in bone marrow cells (Fig. 7, middle).
Discussion
Activation of STAT5 is detected in Philadelphia1 (Ph1)
cell lines (23–26), in hematopoietic cell lines ectopically
expressing BCR/ABL (27), and in CML primary cells (55).
However, the mechanism(s) of BCR/ABL-dependent acti-
vation of STAT5 and its role in BCR/ABL leukemogene-
sis are essentially unknown. In this study, we investigated
the mechanism(s) of BCR/ABL-regulated STAT5 activa-
tion and assessed its role in BCR/ABL leukemogenesis.
Mechanisms of STAT5 Activation by BCR/ABL. In
32Dcl3 cells transfected with various BCR/ABL mutants,
STAT5 activation was dependent on intact SH3 and SH2
domains that might be required for a direct interaction with
STAT5 or with intermediate molecules linking structurally
and/or functionally BCR/ABL and STAT5. Since only a
small amount (if any) of BCR/ABL was usually detectable
in complex with STAT5 (data not shown), it is possible
that the BCR/ABL-STAT5 complex is too unstable for
ready detection or that the interaction of BCR/ABL with
intermediate molecules is the primary mechanism of STAT5
activation. In their COOH-terminal portions, STAT5A
and STAT5B have two proline-rich regions that may be
recognized by the SH3 domain of BCR/ABL or by an
adaptor protein(s) serving as a bridge between BCR/ABL
and STAT5. The interaction between the STAT5 P.Tyr(s)
and the BCR/ABL SH2 domain does not seem to be in-
volved in STAT5 activation, because the R1053L substitu-
tion in the FLVRES motif of the BCR/ABL SH2 domain,
which reduces the ability of the SH2 domain to bind P.Tyr
(64), did not interfere with STAT5 activation even when
the BCR/ABL SH3 domain was deleted or carried the
P1013L mutation, which impairs the interaction with pro-
line-rich motifs (65). However, deletion of the entire SH2
domain from BCR/ABL in the context of a mutant lack-
ing the SH3 domain or carrying the P1013L substitution
prevented BCR/ABL-dependent STAT5 activation, sug-
gesting that a portion of the BCR/ABL SH2 domain, dis-
tinct from the P.Tyr binding motif (FLVRES), is essential
for this effect. One possibility is that the STAT5 SH2 do-
main recognizes one of the tyrosines in the BCR/ABL
SH2 domain, or that the BCR/ABL SH2 domain interacts
with STAT5 or with another intermediary protein(s) in a
non-P.Tyr-dependent manner (57).
The BCR/ABL SH31SH2 domains may also create a
“pocket” required for the direct or indirect activation of
STAT5. There is evidence to suggest intramolecular con-
tact between the BCR/ABL SH3 and SH2 domains, col-
laboration between these domains, and mutual functional
influence of one domain on the other (66).
The signaling pathways stimulated by BCR/ABL SH3
and SH2 domains that lead to STAT activation are un-
known. RIN1, the Ras binding protein (67) that interacts
simultaneously with both the SH3 and SH2 domains of
BCR/ABL (68), might not be involved in this process be-
Figure 7. STAT5-DAM rescues the growth factor–independent col-
ony formation of murine bone marrow cells expressing STAT5 activa-
tion–deficient BCR/ABL SH31SH2 mutants. Murine bone marrow
cells were coinfected with BCR/ABL and/or STAT5 retroviruses and 72 h
later were assayed for BCR/ABL expression, STAT5 DNA binding ac-
tivity, and methylcellulose colony formation. (Top) Expression of BCR/
ABL and actin proteins detected by Western blot analysis in total cell ly-
sates from infected marrow cells. (Middle) STAT DNA binding activity
measured by EMSA in nuclear extracts from cells starved of growth fac-
tors and serum for 12 h. (Bottom) Methylcellulose colony formation of
infected cells cultured in the absence or presence of threshold concentra-
tions (0.1 U/ml) of murine recombinant IL-3. Results (mean 6 SD) are
from three independent experiments.1237 Nieborowska-Skorska et al.
cause it does not coimmunoprecipitate with STAT5 (data
not shown). The PI-3k/Akt pathway, which is affected by
mutation/deletion of the BCR/ABL SH2 domain (21), is
also probably not essential for STAT activation because no
STAT activation was detected in 32Dcl3 cells expressing
Akt dominant-active mutants (data not shown).
A recent report showed that the COOH-terminal por-
tion of the v-ABL oncogene is required for the interaction
with JAK1 and the activation of STAT5 (69), suggesting
that BCR/ABL and v-ABL use different mechanisms to
activate STAT5. Unlike v-Abl, BCR/ABL neither associ-
ates with nor phosphorylates JAK1 or JAK2 in hematopoi-
etic cells (24, 26, 55, and our unpublished results). The
mechanism(s) of BCR/ABL-dependent activation of STAT5
seems similar to that induced by v-SRC. Like BCR/ABL,
v-SRC does not phosphorylate JAKs in 32Dcl3 cells (43).
In addition, BCR/ABL-STAT5 and v-SRC-STAT5 com-
plexes are not readily detectable (26, 43, and this paper),
and both oncoproteins require the SH3 and the SH2 do-
mains to activate STATs (43 and this paper). Perhaps the
characterization of proteins interacting with the SH3-SH2
segment of BCR/ABL may shed light on the mechanism(s)
of STAT5 activation, even if other BCR/ABL domains
might be important in this process.
BCR/ABL-dependent STAT5 Activation Is Important for
Protection from Apoptosis and Growth Factor Independence. The
role of STAT5B in BCR/ABL-dependent protection from
apoptosis and induction of growth factor–independent prolif-
eration was assessed after perturbation of STAT5 activity us-
ing two different strategies: (a) coexpression of WT BCR/
ABL and STAT5B-DNM; or (b) coexpression of STAT5 ac-
tivation–deficient BCR/ABL mutants and STAT5B-DAM.
Transient expression of STAT5B-DNM induced apop-
tosis and arrested cell cycle progression in the majority of
BCR/ABL-expressing cells cultured in the absence of se-
rum and/or IL-3. This partial inhibitory effect could be
due to expression levels of STAT5B-DNM insufficient to
block STAT5 activity in some cells. However, it is more
likely that more than one independent pathway is required
for the reduced apoptosis susceptibility and the growth fac-
tor-independent proliferation of BCR/ABL-expressing
cells. Indeed, the dominant-active STAT5B mutant in-
duced transient protection from apoptosis in 32Dcl3 cells,
but upon expression in cells cotransfected with STAT5 ac-
tivation–deficient BCR/ABL SH31SH2 mutants (DSH31
DSH2 or P1013L1DSH2), the double-transfectants were
permanently protected from apoptosis and proliferated in a
growth factor–independent manner.
Several proteins such as Bcl-2 (22), Bcl-XL (70), Ras
(71), and mitochondrial Raf (72) have been implicated in
the transduction of antiapoptotic signals generated by
BCR/ABL. Bcl-2 downmodulation was observed in cells
expressing various BCR/ABL SH31SH2 domain mutants,
regardless of their ability to activate STAT5 (data not
shown). The expression of functional GTP-bound Ras was
upregulated in cells expressing STAT5 activation-deficient
BCR/ABL mutants (this paper). Also, STAT5 was acti-
vated in cells expressing the D176–426 BCR/ABL mutant,
which neither activates mitochondrial Raf-1 nor protects
transfected cells from apoptosis induced by IL-3 withdrawal
(72). There might be a functional link between STAT5
and Bcl-XL, as the Bcl-XL promoter contains a STAT5
binding site (73); however, the expression of Bcl-XL was
not regulated by BCR/ABL in growth factor–starved
32Dcl3 cells (data not shown). Thus, BCR/ABL-depen-
dent activation of STAT5 may involve a novel antiapop-
totic mechanism(s). Our data on the antiapoptotic effect of
STAT5-DAM are consistent with previous reports indicat-
ing that STAT5 plays an important role in antiapoptotic
pathways regulated by IL-2 (34) and that STAT5 regulates
the expression of the A1 protein (52), an antiapoptosis
member of the Bcl-2 family (74).
The DSH31R1053L or P1013L1R1053L BCR/ABL
mutant was able to activate STAT5 but protected only 50–
60% of the cells from apoptosis induced by IL-3 withdrawal.
Reduced susceptibility to apoptosis of 32Dcl3 cells express-
ing STAT5 activation-deficient BCR/ABL SH31SH2 mu-
tants (DSH31R1053L and P1013L1R1053L) and STAT5B-
DAM, in comparison to cells expressing BCR/ABL SH31
SH2 mutants activating endogenous STAT5 (DSH31
R1053L and P1013L1R1053L), may be due to several
reasons. First, ectopically expressed STAT5B-DAM may
stimulate its downstream effectors more effectively than
endogenous STAT5 activated by BCR/ABL mutants. In
accordance with this possibility, A1 mRNA levels appear
to be higher in clones expressing the BCR/ABL DSH31
DSH2 mutant and STAT5B-DAM than in clones trans-
fected with the BCR/ABL DSH31R1053L mutant (data
not shown). Second, proapoptotic signaling molecules such
as SHIP (75) could be differentially regulated by the various
BCR/ABL SH31SH2 mutants (76) and might interfere
with antiapoptotic activity of STAT5. Third, proteins
modulating STAT5 activity such as CRKL (77) or CIS
(78) could be differentially activated in hematopoietic cells
by the BCR/ABL SH31SH2 mutants.
Cells expressing STAT5-activating BCR/ABL SH31
SH2 mutants (DSH31R1053L or P1013L1R1053L) and
surviving in growth factor–free medium became readily
growth factor independent. Thus, although not sufficient,
STAT5 activation might be necessary for BCR/ABL-
dependent cell cycle progression (79). Indeed, expression
of STAT5B-DAM in cells transfected with STAT5 activa-
tion-deficient BCR/ABL SH31SH2 mutants not only re-
stored protection from growth factor deprivation–induced
apoptosis, but also significantly increased the percentage of
cells synthesizing DNA, suggesting that STAT5 synergizes
with STAT5 activation–deficient BCR/ABL SH31SH2
mutants to stimulate growth factor–independent prolifera-
tion. However, it cannot be excluded that survival signals
induced by constitutively active STAT5 are necessary to
complement the mitogenic signals stimulated by the STAT5
activation–deficient BCR/ABL SH31SH2 mutants. Some
of the 32Dcl3 clones expressing STAT5 activation–defec-
tive BCR/ABL SH31SH2 mutants became competent for
STAT5 activation after long-term culture. This phenome-
non was associated with the emergence of growth factor1238 Role of STAT5 in BCR/ABL Leukemogenesis
independence, and could reflect the use of an alternative
signaling pathway(s) by BCR/ABL mutant (80, 81), the re-
activation of an autocrine loop for growth factor produc-
tion which has been shown to require an intact BCR/ABL
SH2 domain (82, 83), or the occurrence of secondary mu-
tations (84) that may induce constitutive activation of
STAT5. The requirement for STAT5 activation in BCR/
ABL-induced abrogation of IL-3 dependence in 32Dcl3
cells is consistent with similar data in v-SRC–transfected
cells (43). The importance of STAT5 in cell cycle progres-
sion was previously suggested, based on the suppression of
DNA synthesis and proliferation in an IL-3–dependent BaF3
cell line expressing a STAT5 dominant-negative mutant
(48). Moreover, STAT5B-DAM induced IL-3–independent
proliferation of BaF3 cells (58). Also, bone marrow progeni-
tors from STAT5A and STAT5A1STAT5B knockout mice
demonstrate a defect in granulocyte-macrophage colony-
stimulating factor–induced proliferation (32, 52).
A Functional STAT5 Activated by SH3 and SH2 Domains
of BCR/ABL Is Required for Leukemogenesis. The involve-
ment of STAT5 activation in BCR/ABL leukemogenesis
was demonstrated by showing that: (a) expression of a domi-
nant-negative STAT5B mutant suppressed the leukemogenic
potential and the transformation (growth factor–independent
colony formation) of BCR/ABL-expressing 32Dcl3 cells or
bone marrow cells, respectively; and (b) a dominant-active
STAT5B mutant rescued leukemogenic potential and growth
factor–independent colony formation of 32Dcl3 cells or pri-
mary bone marrow cells, respectively, expressing STAT5 ac-
tivation-defective BCR/ABL SH31SH2 mutants.
BCR/ABL-dependent leukemogenesis of 32Dcl3 cells
and transformation of primary mouse marrow cells was
markedly, but not completely, inhibited by coexpression of
dominant-negative STAT5B mutant. The simplest expla-
nation for this partial inhibitory effect is that expression
levels of STAT5B-DNM were insufficient to completely
block STAT5 activity. Indeed, BCR/ABL-induced STAT5
DNA binding activity was not completely inhibited by co-
expression of the dominant-negative STAT5 mutant. How-
ever, in light of the results of the complementation assays
(see below) it seems likely that the full potential of BCR/
ABL to transform bone marrow cells rests in the activation
of several independent pathways.
The rescue of the leukemogenic potential of the STAT5
activation–deficient SH31SH2 BCR/ABL mutant by
dominant active STAT5 was not complete, as indicated by
the slower development of disease in mice injected with
mutant-expressing cells than in mice injected with cells ex-
pressing WT BCR/ABL. Most likely, other signaling path-
ways, such as the PI-3k/Akt pathway, are affected by dele-
tion/mutation in the SH31SH2 domains of BCR/ABL
(21), and are not rescued by STAT activity.
The higher frequency of CNS involvement, compared
with other organs, in mice injected with mutant BCR/
ABL and STAT5B-DAM coexpressing cells might be due
to STAT5-dependent transactivation of a gene(s) required
for homing to CNS. On the other hand, the earlier death
from leukemia in mice injected with WT BCR/ABL-
expressing cells might explain the apparent lower frequency
of CNS involvement since large leukemic infiltrates in the
CNS would not have formed at the time of necropsy.
The role of STAT5 in BCR/ABL-mediated transformation
was also confirmed in transformation (growth factor–indepen-
dent colony formation) assays with primary mouse bone mar-
row cells. STAT5 activation–deficient BCR/ABL SH31SH2
mutants were completely defective in transformation; expres-
sion of dominant-active STAT5B mutant rescued the trans-
formation potential of these BCR/ABL mutants, but not of
the kinase-deficient K1172R BCR/ABL. However, the im-
paired leukemogenic potential of SH31SH2 domain BCR/
ABL mutants is not only due to lack of STAT5 activation. In-
deed, the ability of STAT5-activating BCR/ABL SH31SH2
mutants (DSH31R1053L and P1013L1R1053L) to trans-
form murine bone marrow cells was significantly diminished
(data not shown), in accordance with previous findings in-
dicating that intact SH3 and SH2 domains are required for
BCR/ABL-mediated transformation (9, 21), and that
STAT5B-DAM restored most but not all transformation po-
tential of STAT5 activation–deficient BCR/ABL SH31SH2
mutants (DSH31DSH2 and P1013L1DSH2). Therefore,
other signaling pathways regulated by BCR/ABL SH31SH2
domains, in addition to STAT5 activation, are required for the
full transformation potential of BCR/ABL. Interestingly, the
transformation potential of the Y177F1R522L1Y793L
BCR/ABL TM, which also does not activate STAT5, was
not rescued by coexpression of STAT5B-DAM. This proba-
bly reflects the inability of activated STAT5 to rescue a BCR/
ABL mutant defective in certain signaling pathways. For
example, the STAT5 activation–deficient BCR/ABL SH31
SH2 mutants were competent for Ras activation, whereas the
BCR/ABL TM was unable to induce an increase of func-
tional GTP-bound Ras (56), suggesting the requirement for
both Ras and STAT5 activation in the leukemogenic poten-
tial of BCR/ABL.
The mechanism(s) whereby STAT5-regulated pathways
are involved in BCR/ABL-dependent transformation of
hematopoietic cells is unknown, but the involvement of
STAT5 effectors with a potential role in proliferation, sur-
vival, and transformation can be postulated based on the
identification of several STAT5-regulated genes. For ex-
ample, STAT5 induces expression of the A1 gene, a mem-
ber of the Bcl-2 family that protects 32Dcl3 cells from apop-
tosis (74, 85). Bfl-1, the human homologue of A1, cooperates
with the E1A oncogene in transformation (86), raising the
possibility that A1 is activated by STAT5B-DAM in cells
expressing STAT5 activation–deficient BCR/ABL SH31
SH2 mutants, and functions as a mediator of the leuke-
mogenic potential of these double-transfectants. The proto-
oncogene pim-1 is also regulated by STAT5 (48) and is in-
volved in leukemic transformation (87). Also, Bfl-1 (A1) and
pim-1 reportedly collaborate with c-myc (87) and c-myb (88),
which are required for BCR/ABL transformation (89, 90).
In conclusion, this study demonstrates that intact BCR/
ABL SH3 and SH2 domains are required for the induction
of STAT5 activity and that a STAT5-dependent path-
way(s) plays a crucial role in BCR/ABL leukemogenesis.1239 Nieborowska-Skorska et al.
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